{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:34:53Z","timestamp":1791977693509,"version":"4.4.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Ethosuximide-associated aplastic anemia (AA) is a rare idiosyncratic disorder with unclear etiology. We report a 17-year-old female with absence seizures on ethosuximide, who was incidentally found to have pancytopenia and a markedly hypocellular marrow (&lt;5% cellularity) with lupus erythematosus (LE) cells. The presence of antinuclear and anti-histone antibodies supported a diagnosis of AA secondary to drug-induced lupus erythematosus. Ethosuximide was discontinued, and prednisone started with marked blood count recovery. Our case is the first to elucidate the particular lupus erythematosus association, as evidenced by the combination of immunologic serology, marrow aplasia, and the presence of marrow LE cells.<\/jats:p>","DOI":"10.1097\/mph.0000000000003011","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T15:00:47Z","timestamp":1740668447000},"page":"131-134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Ethosuximide-associated Aplastic Anemia Likely Due to Drug-induced Lupus Erythematosus: A Case Report With Immunologic Insights"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-236X","authenticated-orcid":false,"given":"Nicholas J.","family":"Dcunha","sequence":"first","affiliation":[{"name":"Department of Pathology & Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia A.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Neurology-Neurophysiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria E.","family":"Diaz-Medina","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Neurology-Neurophysiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tarek","family":"Elghetany","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology"},{"name":"Department of Pediatrics, Section of Hematology & Oncology, Baylor College of Medicine"},{"name":"Texas Children\u2019s Hospital, Texas Children\u2019s Cancer and Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A.","family":"Bertuch","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Hematology & Oncology, Baylor College of Medicine"},{"name":"Texas Children\u2019s Hospital, Texas Children\u2019s Cancer and Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-6991","authenticated-orcid":false,"given":"Choladda V.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology"},{"name":"Texas Children\u2019s Hospital, Texas Children\u2019s Cancer and Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"R1-20250628","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10072-014-1701-0","article-title":"Anticonvulsant drugs and hematological disease","volume":"35\ufeff","author":"Verrotti","year":"2014","journal-title":"Neurol Sci"},{"key":"R4-20250628","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0031-6997(25)00046-8","article-title":"Antiepileptic drugs pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds","volume":"42","author":"Rogawski","year":"1990","journal-title":"Pharmacol Rev"},{"key":"R6-20250628","first-page":"18","article-title":"Ethosuximide induced lymphadenopathy\u2014a case report","volume":"47","author":"Ojinnaka","year":"2001","journal-title":"Cent Afr J Med"},{"key":"R7-20250628","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/jnnp.2005.064923","article-title":"Drug induced pseudolymphoma secondary to ethosuximide","volume":"76","author":"Masruha","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-20250628","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0887-8994(94)90093-0","article-title":"Aplastic anemia following therapy for absence seizures with ethosuximide","volume":"11","author":"Massey","year":"1994","journal-title":"Pediatric neurology"},{"key":"R9-20250628","doi-asserted-by":"crossref","first-page":"175","DOI":"10.15264\/cpho.2018.25.2.175","article-title":"A case of ethosuximide-induced aplastic anemia successfully treated with methylprednisolone pulse therapy","volume":"25","author":"Kang","year":"2018","journal-title":"Clin Pediatr Hematol-Oncol"},{"key":"R10-20250628","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/09612033241245078","article-title":"Drug-induced lupus erythematosus in childhood: case-based review","volume":"33","author":"Kaya Akca","year":"2024","journal-title":"Lupus"},{"key":"R11-20250628","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/40.7.826","article-title":"The LE cell","volume":"40","author":"Hepburn","year":"2001","journal-title":"Rheumatology"},{"key":"R12-20250628","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ajcp\/101.1.65","article-title":"Practice parameter--the lupus erythematosus cell test. An obsolete test now superseded by definitive immunologic tests","volume":"101","author":"Conn","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"R13-20250628","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/ijn.IJN_249_19","article-title":"The LE cell\u2014a forgotten entity","volume":"31","author":"Sathiavageesan","year":"2021","journal-title":"Indian J Nephrol"},{"key":"R14-20250628","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","article-title":"Clinical interpretation of anti-nuclear antibody tests in systemic rheumatic diseases","volume":"19","author":"Satoh","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R15-20250628","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/25785826.2022.2060168","article-title":"Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus","volume":"45","author":"Lee","year":"2022","journal-title":"Immunol Med"},{"key":"R16-20250628","doi-asserted-by":"crossref","first-page":"494\ufeff","DOI":"10.1001\/archderm.140.4.494","article-title":"The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus","volume":"140","author":"Zirwas","year":"2004","journal-title":"Arch Dermatol"},{"key":"R17-20250628","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R18-20250628","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T12:00:34Z","timestamp":1751112034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003011","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"2024-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}